Monoclonal anti Androgen Receptor (AR441 + DHTR/882)

识别110kDa的蛋白质，即雄激素受体（AR）。它与全长度新接受体反应。它不会与雌性激素，孕酮或者糖皮质激素接受体发生交叉反应。雄性激素AR的表达与病理分级成反比，比如高度分化的前列腺癌与分化不良的前列腺癌相比有着更高的表达量。在前列腺癌中，雄性激素受体AR被当作激素响应性的标志，因此它在确诊病人病症过程中很有用。抗雄激素接受体在临床上从皮肤上促结缔组织增生的毛上皮瘤区分morpheaform 细胞癌(mBCC)上非常有效。Mab在染和石蜡切片上效果JJ。
Recognizes a protein of 110kDa, which is identified as androgen receptor (AR). It reacts with full length, and the newly described A form of the receptor. It does not cross react with estrogen, progesterone, or glucocorticoid receptors. The expression of AR is reportedly inversely correlated with histologic grade i.e. well differentiated prostate tumors show higher expression than the poorly differentiated tumors. In prostate cancer, AR has been proposed, as a marker of hormone-responsiveness and thus it may be useful in identifying patients likely to benefit from anti-androgen therapy. Anti-androgen receptor has been useful clinically in differentiating morpheaform basal cell carcinoma (mBCC) from desmoplastic trichoepithelioma (DTE) in the skin.This MAb is superb for staining of formalin/paraffin tissues.